Eli Lilly and Company (NYSE:LLY – Get Free Report) declared a quarterly dividend on Monday, June 24th, Wall Street Journal reports. Shareholders of record on Thursday, August 15th will be paid a dividend of 1.30 per share on Tuesday, September 10th. This represents a $5.20 annualized dividend and a yield of 0.57%. The ex-dividend date of this dividend is Thursday, August 15th.
Eli Lilly and Company has raised its dividend payment by an average of 15.2% annually over the last three years. Eli Lilly and Company has a dividend payout ratio of 27.0% indicating that its dividend is sufficiently covered by earnings. Analysts expect Eli Lilly and Company to earn $19.44 per share next year, which means the company should continue to be able to cover its $5.20 annual dividend with an expected future payout ratio of 26.7%.
Eli Lilly and Company Price Performance
Eli Lilly and Company stock opened at $907.95 on Wednesday. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $966.10. The firm has a market cap of $862.92 billion, a P/E ratio of 133.72, a P/E/G ratio of 1.81 and a beta of 0.41. The business’s fifty day moving average is $873.64 and its two-hundred day moving average is $800.31.
Insider Buying and Selling at Eli Lilly and Company
Analyst Ratings Changes
A number of equities research analysts recently commented on LLY shares. Morgan Stanley reiterated an “overweight” rating and issued a $1,023.00 price objective on shares of Eli Lilly and Company in a report on Friday, July 5th. JPMorgan Chase & Co. lifted their target price on Eli Lilly and Company from $900.00 to $1,000.00 and gave the company an “overweight” rating in a research report on Thursday, July 11th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their price target for the company from $725.00 to $1,025.00 in a research note on Monday. Bank of America lifted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Argus boosted their price target on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Two investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $945.35.
View Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Read More
- Five stocks we like better than Eli Lilly and Company
- EV Stocks and How to Profit from Them
- Chipotle Mexican Grill: Take a Bite of This Smoking Hot Deal
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Why O’Reilly Automotive Stock Could Be a Long-Term Winner
- Bank Stocks – Best Bank Stocks to Invest In
- Hut 8 Corp.’s Earnings: Is Crypto Mining About to Change?
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.